RMTI just issued press release and I've been scouring twitter with no answer.
I thought from the briefing documents that the committee was going to be asked to vote on two questions, the obvious question regarding hemoglobin maintenance, but also as to whether Triferic reduces ESA use.
I don't have a position but have been watching intently as shorts/longs duked it out.
Is there somewhere one can listen to recording of the meeting?
Just to put Feuerstein in perspective, he's tweeted a couple of times about how OHRP is failing to publish the data on the second cohort from the Phase II trial, suggesting they are hiding something.
Would somebody please tell @adamfeuerstein that the second cohort won'f finish treatment until early 2015 as OHRP has stated on multiple occasions. (I'd tell Adam myself but he has blocked me on twitter)
That is just one blatant example of Adam's rush to judgement. I think Adam resents the fact that OHRP doesn't do any R&D and that they are just exploiting an asset that they picked up on the cheap. I think he's stuggling to accept that maybe there is actually some efficacy even if the company doesn't fully understand the mechanism of action.
Feuerstein seems to have some kind of chip on his shoulder just like Optimist_77, Feuerstein frequently revels in the misfortune of others. Can you say schadenfreude!.
As for Optimist_77, as I've said before, I pity the people who have to actually interact with this guy in person.
Results of Ebola test expected within 24 hours.
Yale Graduate Student who recently traveled to Liberia was admitted to Yale New Haven Hospital today with Ebola Like Symptoms. Hospital currently doing news converences being broadcast on WTNH, channel *. Patient is in isolation.
Press release just out.
Fascinating development. FDA has allowed primary endpoint to be changed to improved visual acuity instead of reduced injections. Makes chances of meeting primary endpoint and FDA approval a heck of a lot better.
Squalamine certainly won't be the $10B blockbuster L10 was calling for, but now the question is... what would market size be as an adjunct?
OK Optimist_77, you twisted bitter old man, have at it.
p.s. Feuerstein couldn't resist a cynical/skeptical tweet predicting doom.
Hey emotion boy, you're still carrying that 200,000lb ($200K) chip on your shoulder, aren't you?
How'd all them expensive put options work out that you bought ahead of PhII data? Pretty much worthless at this point, eh?
Remember back in February how YOU ran Phakosurgeon off the board when he was he skeptical of squal??? That was back when you had your cranium firmly inserted in L10's sphinctor as the stock was rising.
It really bothers you that I layed my cards on the table, played the trade without emotion and made money, doesn't it?
To quote Don Henley of the Eagles..... 'you keep carrying that anger, it will eat you up inside'
Maybe you and Richmando can car pool to anger management classes.
With the millions tha Almenoff pocketed selling Furiex Pharma, why is she wasting time on penny ante purchases. Tell me it's not a facade.
How about just running and growing the business? Investor relastions campaigns takes up managements time and cost money.
That #$%$ just moves the stock price in the short term, so unless the company is needs to sell shares to grow, it's actually a disservice to shareholders who are in for the long term.
I say we let Mr. Ulland keep doing what he's doing. But I will say one thing, at 73 years old, maybe it's time to get someone younger running the company day to day and let him run the board.
Hey planet_Fukknutts. You really have some self esteem issues, don't you?
Just took a look at your last dozen or so posts. Pretty much nothing useful in any of them and full of criticism of anything anyone else has to say.
I've been on this earth long enough to know that people who make posts like yours are unhappy with themselves and bully others to make themselves feel better. I pity anyone who has to interact with you on a day to day basis.
Over the weekend I saw a rerun of the movie 'The Breakfast Club', John Bender, that pretty much sums you up.
p.s. Your first posts in three months, you been in rehab or county jail? Only a dozen posts in the last two years, having trouble paying for your dial up?
Cut in half on the offering. OUCH.
That said, I like what I see here now. I grabbed some shares this morning sub $5.
With some working capital they can hire sales staff and build inventory for growth. Looking forward to next investor call to ask a few questions.....
Which Opti are you talking about, the complete jerk who insulted and drove skeptics off the board with regularity on the way up, or the jaded and bitter one who insulted anyone who had a shred of optimism ahead of the data?
They both took a bath in this stock.
Blow it out your #$%$! What's your problem, you take a m#$%$ive loss on OHRP like that other clown Optimist_77?
Don't #$%$ociate me with Livermore_10 or anybody else. I was never a lemming of his, but if my memory serves me well, you drank your share of his Kool-Aid. I met him at the shareholder meeting, he was real AND he was a fallible human.
Before the pain of your financial loss causes you to make any more inaccurate accusations about me, YOU SHOULD READ ALL OF MY POSTS on OHRP board, you'll need to go back to the middle of 2013.
After that, if for some emotional reason you want to engage in a tit-for-tat argument, have at it.
Tell me where my credibility is in question, site my specific posts and I'll defend myself.
Until you do that, you are just another guy who made bad trading decisions and wants to blame it on somebody else, just like Optimist_77.
Livermore_10's cost basis on his 80K+ shares of OHRP was somewhere around $2.70 post reverse-split, #$%$uming from his month plus absence on his private board that he has liquidated, he had a triple, and a $400K profit. My profit's were only a fraction of that, but they DEFINITELY were nice profits. I never told anyone to buy this stock.
Who lost more money on OHRP, You or Optimist_77? Or are you still setting on a big money losing position hoping for that one day pop that lets you exit with a little bit less of a loss?
When it comes to trading/investing, hope is NOT a viable strategy.
Nobody forced you to press the 'Buy' button, #$%$, NOBODY!
p.s. I'm not a StuartCreekFarms lemming either. But if anybody on this board was credible, it was him. Knowledgeable, level headed and well reasoned.
Hey Stuart, AAVL IPO coming this week, any thoughts?
Gene therapy for eye diseases.
Adage Capital who were PBYI investors are AAVL investors too.
charles, now you are stuck in that dog LPTN and OHRP (remember, you told us you were long OHRP as a hedge).
Maybe Pancoast will take you in a ride in his Lamborgini after the LPTN shareholder meeting this week. After all, you and the other LPTN shareholders bought it for him. Zoom, zoom!
Still waiting to see who buys that iSONEP option from PFE, when was that supposed to happen, April? Can you ask Pancoast about that for me? Thanks!
Correct me if I'm wrong, there was no statistical significance to the visual acuity differences? How often do we actually see statistical significance even in PhII small sample that disappears when we have 300+ patients as will be required in PhIII? And since squalamine didn't decrease lesion size as the calmodulin binding theory suggested, we don't really know what it's doing in there, do we? Help me understand, how do we get visual acuity improvements without reducing lesion size? Couldn't the acuity difference seen thus far end up being just a statistical anomoly? As a lay person I have no way of putting into perspective how significant an improvement of 10.4 letters vs 6.3 letters is or how credible the idea of improved visual acuity without reducing lesion size is.
On the conference call, Slakter even had to beg off on how/why squalamine improved visual acuity since it didn't reduce injections, the primary endpoint. To quote Slakter 'It APPEARS squalamine is exerting it's effect in a more basic level, at the pathophysiology of the disease, at the neovascular tissue, at fibrosis and inflamation that MIGHT be associated with it.' I'd feel a lot better about squalamine if Slakter said WE KNOW that squalmine is improving visual acuity because it...... ('It appears' and 'might' don't give me a lot of confidence we know just what is going on).
Also on the call Slakter made it clear there is no provision or plan to tweek the retreatment criteria in the current trial and no plan to start a PhIII trial until PhII is complete. Thus any trial with more favorable retreatment criteria is going to need to go through the entire FDA process. That's going to take another two years.
Maybe a big pharma will be willing to throw some seed money at OHRP to keep them going, but for now we have significant cash burn from the current trial AS WELL AS FUNDING SKS and it's early stage trials before we ever see if the visual improvements are actually real.
Adam feeling his oats.
Remember back on April 25th when Opimist_77 was in full rant mode he babbled on about how he had researched 12 biotech stocks that had announced PhII interim or final data and that all of them we up 30-50% in the 60 days leading into the announcement.
He never did disclose the names, but nobody ever expected it.
Our resident know-it-all asserts that 'price is everything'. The market knows all! If the price isn't rising, RESULTS WILL BE BAD! Some woman said it on Wall $treet Week 15 years ago, so it MUST be flawlessly true.
Somewhere in the thread that followed, Mr. Know-it-all challenged us to find one biotech stock that had fallen ahead of positive PhII results.
By chance, over the weekend I was doing a little historical due diligence (something that seems to challenge wonderboy) and took a look at the price action of a small, relatively unknown biotech that was doing a trial in the wet AMD space a while back. Maybe you've heard of the company, it's called REGENERON. Symbol is REGN, just in case Optimist hasn't run across them in his extensive due diligence. REGN had zero product revenue and was burning $20MM cash per qtr.
On March 27, 2007 (a Tuesday morning a week after options expiration), REGN announced positive Interim PhII results for an obscure drug they called VEGF-Trap (you might be familiar with it's new name, they call it Eylea).
So how did REGN stock perform for the 30 & 60 days ahead of PhII interim results? It HAD to be up 50% if you believe douchebagg_77, right? Nope, that wasn't quite the case. For 30 days prior to results REGN was DOWN 9%, for 60 days ahead of results it was DOWN 4%. The stock was actually DOWN 23% from it's high a few months prior.
Amount I can lose on my OHRP investment?.................................. Zero, I'm riding house money.
Value I gain making fun of Jerkwadd_77 who has lost a boatload on OHRP? .............. Priceless!